MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13000-025-01697-0

Медицинская библиотека · Diagnostic pathology · 2025

Evaluating sensitivity of NGS-based mutation detection across diverse sample types in prostate cancer.

Jiang Kui, Dai Zhihong, Chen Jiaqiang, Gao Ziping, Tong Heyao, Liu Hongruo, Huang Gena, Liu Fang, Ma Ya, Pan Evanki, Yin Jiani, Yao Lulu, Wang Liang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Prostate cancer (PCa) is one of the most common malignancies affecting men, with primary treatments involving surgery, radiotherapy, and hormonal therapy. The introduction of precision medicine and next-generation sequencing (NGS) has profoundly influenced the clinical management of PCa, particularly by enabling the assessment of genetic alterations that guide treatment decisions. Liquid biopsy using diverse sample types, including plasma, urine, and semen, offers non-invasive alternatives to tissue biopsies. This study sought to compare the performance of NGS-based mutation detection across various sample types in PCa patients.

METHODS

Thirty-seven PCa patients, diagnosed with intermediate to advanced stages (II-IV), were enrolled. All collected samples, including tissues (n = 34), plasma (n = 37), urine (n = 32), and seminal fluids (n = 9), underwent targeted NGS of 437 cancer-related genes. The detection sensitivity, mutational landscape, and maximum variant allele frequencies (MVAFs) were compared across different sample types.

RESULTS

Tissue samples, serving as the gold standard, achieved a 100% mutation detection rate. Plasma and urine samples demonstrated high detection sensitivities, reaching 67.6% and 65.6%, respectively, while semen samples showed a lower detection rate of 33.3%. Mutations in FOXA1, SPOP, and TP53 were commonly detected across most sample types with comparable prevalence. AR mutations were observed with similar frequencies in plasma and semen samples, but were absent in tissue and urine samples. The average MVAFs were at similar levels among tissue, plasma, urine, and semen, although urine sediment samples exhibited the lowest MVAFs. Advanced disease stages correlated with increased circulating tumor DNA (ctDNA) detection in both plasma and urine samples. No significant survival advantage associated with ctDNA negativity was observed, likely due to the small sample size.

CONCLUSIONS

This study validates the utility of urine and plasma samples as non-invasive and sensitive liquid biopsy options for PCa, showing comparable ctDNA detection rates. Seminal fluid samples also demonstrate potential, despite current sampling challenges. These findings offer insights into the advantages of different sampling methods for PCa detection and reinforce the clinical utility of liquid biopsies in PCa management.

Для цитирования: Jiang Kui, Dai Zhihong, Chen Jiaqiang, Gao Ziping, Tong Heyao, Liu Hongruo, Huang Gena, Liu Fang, Ma Ya, Pan Evanki, Yin Jiani, Yao Lulu, Wang Liang. Evaluating sensitivity of NGS-based mutation detection across diverse sample types in prostate cancer.. Diagnostic pathology. 2025. DOI: 10.1186/s13000-025-01697-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.